- Home
- DRTS vs LYEL Comparison
DRTS vs LYEL Comparison
Compare DRTS & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRTS
- LYEL
- Stock Information
- Founded
- DRTS 2015
- LYEL 2018
- Country
- DRTS Israel
- LYEL United States
- Employees
- DRTS N/A
- LYEL N/A
- Industry
- DRTS Medical/Dental Instruments
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- DRTS Health Care
- LYEL Health Care
- Exchange
- DRTS Nasdaq
- LYEL Nasdaq
- Market Cap
- DRTS 211.7M
- LYEL 207.7M
- IPO Year
- DRTS N/A
- LYEL 2021
- Fundamental
- Price
- DRTS $2.55
- LYEL $0.51
- Analyst Decision
- DRTS Strong Buy
- LYEL Sell
- Analyst Count
- DRTS 2
- LYEL 2
- Target Price
- DRTS $8.00
- LYEL $1.00
- AVG Volume (30 Days)
- DRTS 32.4K
- LYEL 861.1K
- Earning Date
- DRTS 03-12-2025
- LYEL 03-11-2025
- Dividend Yield
- DRTS N/A
- LYEL N/A
- EPS Growth
- DRTS N/A
- LYEL N/A
- EPS
- DRTS N/A
- LYEL N/A
- Revenue
- DRTS N/A
- LYEL $61,000.00
- Revenue This Year
- DRTS N/A
- LYEL N/A
- Revenue Next Year
- DRTS N/A
- LYEL N/A
- P/E Ratio
- DRTS N/A
- LYEL N/A
- Revenue Growth
- DRTS N/A
- LYEL N/A
- 52 Week Low
- DRTS $1.75
- LYEL $0.48
- 52 Week High
- DRTS $4.39
- LYEL $3.15
- Technical
- Relative Strength Index (RSI)
- DRTS 39.29
- LYEL 41.67
- Support Level
- DRTS $2.60
- LYEL $0.53
- Resistance Level
- DRTS $2.68
- LYEL $0.63
- Average True Range (ATR)
- DRTS 0.14
- LYEL 0.06
- MACD
- DRTS 0.01
- LYEL -0.01
- Stochastic Oscillator
- DRTS 28.26
- LYEL 17.32
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.